ACT-02 Changes in Recurrence Pattern and Prognosis of Glioblastoma after Approval of Bevacizumab as First-line Application

Introduction: There exist controversies on recurrence and aggressiveness after use of first-line bevacizumab (BEV) which has been approved in Japan and proven to be beneficial. Therefore, we analyzed the clinical impact of BEV approval by investigating the overall clinical course and glioblastoma (G...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neurooncol Adv
Autors principals: Funakoshi, Yusuke, Hata, Nobuhiro, Kuga, Daisuke, Hatae, Ryusuke, Sangatsuda, Yuhei, Fujioka, Yutaka, Takigawa, Kosuke, Mizoguchi, Masahiro
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Supplement Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7699102/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa143.032
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars